OFF-BRAND GLEEVEC: A COST-EFFECTIVE ALTERNATIVE?

The emergence of common imatinib represents a significant opportunity for patients battling chronic myeloid leukemia and other conditions. Original brand-name imatinib, branded as Gleevec, carries a considerable price cost, frequently causing accessibility for some individuals. Common versions, t